TriangleNCT01673646 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- other Details
- The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- After the first 3 months, pasireotide LAR dose could be increased for efficacy or decreased for safety at any time during the study.
- point Of Contact
- novartis.email@novartis.com
- organization
- Novartis Pharmaceuticals
- phone
- 862-778-8300
- title
- Clinical Disclosure Office
Complete source fields
- certain Agreement
- other Details
- The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- After the first 3 months, pasireotide LAR dose could be increased for efficacy or decreased for safety at any time during the study.
- point Of Contact
- novartis.email@novartis.com
- organization
- Novartis Pharmaceuticals
- phone
- 862-778-8300
- title
- Clinical Disclosure Office
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice